Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors
Launched by CASE COMPREHENSIVE CANCER CENTER · Mar 21, 2006
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES:
* Define the prevalence of audiometrically detectable hearing loss in patients with solid tumors treated with oxaliplatin.
* Describe the association of chemotherapy-induced peripheral neuropathy (CIPN) and audiometrically detectable hearing loss in these patients.
* Describe the association of CIPN and patient self-reported scales including, Peripheral Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory.
OUTLINE: This is an exploratory study.
Patients will complete three self-reported questionnaires including the Peripheral Neuropathy Sc...
Gender
ALL
Eligibility criteria
- DISEASE CHARACTERISTICS:
- • Diagnosis of solid tumor
- • Received an oxaliplatin-containing chemotherapy regimen within the past 15 months\* NOTE: \*If oxaliplatin was omitted from the patient's most recent chemotherapy regimen due to ototoxicity, the patient is still eligible for participation in this study
- • No known CNS metastases
- PATIENT CHARACTERISTICS:
- • No history of spinal injuries
- • ECOG performance status 0-3
- • No history of chronic renal failure
- • No known HIV/AIDS
- PRIOR CONCURRENT THERAPY:
- • See Disease Characteristics
About Case Comprehensive Cancer Center
Case Comprehensive Cancer Center is a leading academic research institution dedicated to advancing cancer care through innovative clinical trials and cutting-edge research. As a National Cancer Institute-designated Comprehensive Cancer Center, it integrates multidisciplinary approaches to cancer prevention, diagnosis, and treatment, fostering collaboration among clinicians, researchers, and patients. The center is committed to translating scientific discoveries into effective therapies, enhancing patient outcomes, and contributing to the global body of cancer knowledge. With a robust portfolio of clinical trials, Case Comprehensive Cancer Center aims to address the unmet needs of cancer patients and drive progress in the fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
Cleveland, Ohio, United States
Patients applied
Trial Officials
Sabarish Ayyappan, MD
Study Chair
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials